Our Stocks to Watch today include UOMO Media Inc. (OTCBB:UOMO), Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), SmartCard Marketing Systems Inc. (OTC: SMKG), Forbes Medi-Tech Inc. (NASD: FMTI), DOR BioPharma, Inc. (OTCBB: DORB), Cell Genesys, Inc. (NASD: CEGE)
Visit http://www.otcpicks.com/ to register for our Daily Market Mover’s Digest Newsletter, and Email Stock Watch Alerts.
UOMO MEDIA INCORPORATED (OTCBB: UOMO)
Detailed Quote: http://www.otcpicks.com/quotes/UOMO.php
Company Profile: http://www.otcpicks.com/uomo-media/uomo-media.htm
UOMO Media Inc. (OTCBB:UOMO) is a publicly trading entertainment company that acquires, produces, manages, and monetizes entertainment-based intellectual property globally. The company is focusing on the development of four core business units: UOMO Digital, UOMO Recorded Music, UOMO Talent Management and UOMO Publishing. There is a massive and ongoing demand for music and entertainment. IFPI estimates that globally, the broader music industry was worth US$130 billion in 2006.
UOMO News:
February 14 - UOMO Producer Tricky Stewart Scores Mariah Carey First Single 'Touch My Body'
"Touch My Body" Written and Produced by UOMO Producer Tricky Stewart, Mariah Carey, and The-Dream Hits Radio This Week
Mariah Carey, the most successful female recording artist in history with total album, single and video sales of more than 160 million worldwide, and Island Def Jam Records announced this week the most eagerly anticipated album of the year, E=MC².
The first single “Touch My Body,” written and produced by Tricky Stewart, Mariah Carey and The-Dream, blasted worldwide on February 12. The release of her new album is due in stores April 15.
Tricky Stewart and Redzone Entertainment, who have an exclusive international management agreement with UOMO Media (OTCBB: UOMO), are having an exceptional year to date. Winning the Grammy in the Best Rap/Sung category for Rihanna’s “Umbrella” featuring Jay Z, has made these producers some of the most sought after commodities in the industry. By rolling out hits for artists such as Rihanna, Britney Spears, and Celine Dion, Tricky Stewart and Redzone have shown consistency with which they create top selling music.
“We congratulate Tricky and Redzone on the commercial release of another great piece of work and are confident that the single ‘Touch My Body’ will be a chart topping success,” commented Mr. Camara Alford, CEO and Chairman of UOMO Media.
RENHUANG PHARMACEUTICALS (OTCBB: RHGP)
Detailed Quote: http://www.otcpicks.com/quotes/RHGP.php
Company Profile: http://www.otcpicks.com/renhuang-pharma/renhuang-pharma.htm
Renhuang Pharmaceuticals, located in Harbin of Heilongjiang Province in Northeast China, is a leading integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products. The Company provides three major product lines including the Acanthopanax-based natural medicinal products, Shark Power Health Care series and Traditional Chinese Medicines. Renhuang's key product line is Acanthopanax-based products, an effective natural medicine in treating depression and melancholy and offering various other health benefits. By controlling an estimated 70% of China's natural resource of Acanthopanax (also known as Siberian Ginseng), the Company has a dominant market position in Acanthopanax-based natural medicines. The Company distributes its products through a multi-layer sales network of over 2000 sales agents. Its products are not only sold nationwide but also exported to Russia and Southeast Asia. Renhuang has established a multi-channel research and development infrastructure composed of in-house researchers, a post-doctoral working center, and collaboration with well known institutions and scientists. In manufacturing, the Company strictly follows the international GMP certified quality standards and system by utilizing cutting-edge technologies, the state of the art equipment, and the proprietary innovative and award winning processes. For more information about Renhuang Pharmaceuticals, visit http://www.renhuang.com/.
RHGP News:
February 14 - Renhuang Pharmaceuticals, Inc. Retains CCG Elite
Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP) ("Renhuang" or "the Company"), a leading pharmaceutical company in China, announced that it has retained CCG Elite to design and execute its investor relations campaign.
Through its GMP certified facilities, the Company manufactures over 200 types of western, traditional Chinese medicines (TCM), and branded pharmaceuticals. The Company sells raw materials and finished products using its extensive distribution network and third party distributors throughout China. Renhuang controls an estimated 70% of China's natural source of Acanthopanax (also known as Siberian Ginseng), a widely used drug for multiple indications, and hence dominates the market for Acanthopanax-based medicinal and nutraceutical products. The Company's distribution network includes over 3,000 sales agents in 70 sales centers across 24 districts, covering over 50% of the greater China. Additionally, Renhuang exports its pharmaceuticals to Russia and Southeast Asia.
Using its strong R&D team, Renhuang performs contract research and development services. Lead pharmaceuticals include: Acanthopanax based natural medicine products for treating depression, melancholy and other illnesses, Biopharmaceuticals (Shark Power Health Care and Ginseng Ointment) for multiple indications, and TCM. For nine months ending July 31, 2007, Renhuang's revenue totaled $20.1 million, and net income was $8.5 million, up 175% from the same period in the prior year.
"Renhuang is a fast growing drug manufacturer and distributor in China," said Mr. Li Shaoming, Chairman & CEO of Renhuang Pharmaceuticals, Inc. "We are very excited to work with CCG Elite to maximize our stockholders' value by improving our visibility with the investment community and with the financial media."
Pharmaceutical sales in China are expected to increase by over 13 percent annually, reaching $24 billion by 2010. Higher demand for pharmaceuticals in China is expected over the coming years due to growing affluence, size of the middle class, and the aging population. Additionally, the Company expects higher demand for its products in the foreign markets over the coming years.
Renhuang has a pipeline of pharmaceuticals including Lyophilized Syringin Powder for Injection, a novel anti-depression Chinese medicine, and plans to distribute them pending the approval from the Chinese State Food and Drug Administration (SFDA). Additional products in development include food antiseptic, immune system and diagnostics. Furthermore, the Company plans to build its brands by further expanding its market share in major cities such as Beijing and Shanghai. Other growth strategies include direct sales of pharmaceuticals to top tier hospitals, and increasing its branded product sales in the highly populated rural China. Additionally, the Company plans to grow through strategic partnership and acquisitions.
"Renhuang is a leading pharmaceutical company with solid manufacturing capabilities, branded products, extensive distribution network, strong R&D team, and an experienced management," said Crocker Coulson, President of CCG Elite. "The Company is well-positioned to take advantage of growing demand for pharmaceuticals in China. Through our integrated investor relations initiatives, we will introduce the Company to fund managers and analysts focusing on high growth equities from China."
ABOUT CCG ELITE
CCG Elite is uniquely positioned to provide an outsourced, high-level investor relations solution that combines in-depth understanding of Asia's corporate culture and economic scene with a direct pipeline into the leading funds and broker-dealers in the United States. CCG Elite is a global, full-service investor relations agency with corporate headquarters in Los Angeles, and offices in New York, Newport Beach, Dallas, Hong Kong, Beijing and Shanghai. For further information, contact CCG Elite or visit the Company's website at http://www.ccgelite.com/.
SMART CARD MARKETING (OTC: SMKG)
"Up 20.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SMKG.php
Smart Card Marketing Systems, Inc. was established in 2003 and is a leading provider of prepaid cards, value smart storage cards and payment processing services. The company’s current as well as long-term goal is enticing national and international organizations with millions of potential customers and vendors, to purchase and market Smart Card’s products. Smart Card plans to achieve this goal by offering a powerful sales organization and merchant reseller marketing program utilizing their GoSmartCard platform. All of Smart Card’s products and services were developed and designed for international markets, and the company will selectively market to new countries and territories with a prudent and financially beneficial plan using existing, proven and experienced strategic alliances.
SMKG News:
February 15 - SmartCard Marketing Systems Inc. (Velocitymoney.com) Signs with SKI Motorsports Associate Sponsor in NASCAR for 2008 NASCAR Season
SmartCard Marketing Systems Inc. (OTC: SMKG) (QYH: Frankfurt) CEO Massimo Barone announced a partnership with SKI Motorsports, which announced the signing of VelocityMoney.com as associate sponsor for its 2008 NASCAR campaign with driver Stanton Barrett. With plans to compete full time in the NASCAR Nationwide Series as well as select NASCAR Sprint Cup Series events, SKI Motorsports owner Chris Lencheski is happy to welcome VelocityMoney.com to the team.
"It's always exciting to introduce a company to NASCAR for the first time," Lencheski said, "and kicking off our partnership in Daytona gives everyone at VelocityMoney.com the opportunity to experience the excitement and pageantry of the 50th running of the Daytona 500."
A newcomer to NASCAR, VelocityMoney.com is a SmartCard Marketing Services, Inc. (Pink Sheets: SMKG - News) company based in San Antonio, TX USA. They specialize in providing payment gateway services for merchants and consumers.
"We are excited by this sponsorship opportunity with SKI Motorsports in NASCAR as it marks an initiative by management to bring consumer awareness to the masses through a reputable sporting association," stated SmartCard Marketing Systems CEO Massimo Barone.
"This will create an excellent launch opportunity for our product in front of millions of viewers," Barone continued. "With SKI Motorsports we believe that they can contribute to the achievement of our goals. In many ways the Velocitymoney.com branding reflects the essence of motorsports presence in North America."
An obvious attraction for companies looking to build brand awareness is the unequaled fan loyalty as well as the exposure opportunities offered through NASCAR's network television package including a split season with FOX and ABC. ESPN will cover the entire Nationwide Series season with SPEED adding a full schedule of weekly shows and at-track coverage.
In addition to plans to run the full Nationwide Series schedule, Barrett and SKI Motorsports hope to take advantage of that exposure by transferring into this weekend's Daytona 500. Barrett will also attempt to qualify for the Coca-Cola 600 at Lowe's Motor Speedway, the Allstate 400 at the Brickyard and the Sharpie 500 at with VelocityMoney.com on board.
ABOUT VELOCITYMONEY.COM
VelocityMoney.com is an established Money Service provider for payment gateway services for merchants and consumers requiring processing of funds, credit cards and pin debit unlike any existing offering in the market off-net or on-net. For more information visit http://www.velocitymoney.com/.
ABOUT SKI & COMPANY
SKI & Company is a boutique marketing communications company servicing the sports and entertainment communities with a large motorsports and high performance automotive industry practice. In 2007, SKI & Company expanded with additional offices in Charlotte, North Carolina and Dubai, United Arab Emirates to complement the existing offices in New York City, New York, London, United Kingdom and Historic Downtown Bethlehem, Pennsylvania.
SKI & Company incorporates a team of sports and brand marketing professionals committed to servicing commercial rights holders in the development of successful marketing partnerships with global sports and entertainment properties. In the motorsports and automotive practice, SKI & Company was appointed in 2004 as the first global agency of record for General Motors Racing to plan, assist, and consult General Motors factory backed and factory supported racing teams with commercial partnerships. Amongst other clients in the SKI & Company automotive practice, most notably are VNU Media's Nielsen Media sports division, Dubai, U.A.E. based Union Properties and FUZE Beverage, LLC.
FORBES MEDI-TECH (NASD: FMTI)
"Up 10.20% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/FMTI.php
Forbes Medi-Tech Inc. is a life sciences company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of life-threatening disease. Our strategy and vision is to develop and market a portfolio of products for the benefit of all consumers, from the healthy person desiring consumer lifestyle products that can help reduce the risk of future disease, to medical patients needing therapeutic prescription products for the treatment of an established ailment. Additional information on Forbes Medi-Tech can be found at http://www.forbesmedi.com/.
FMTI News:
February 14 - Forbes Medi-Tech Issues Results from Special General Meeting
Forbes Medi-Tech Inc. (NASD: FMTI) (Toronto: FMI) announced that security holders have approved the Company's corporate reorganization. For resolutions one and two, “Reduction in Stated Capital” and “Name Change” respectively, over 88% of votes cast were in favor of the resolutions.
For resolution three, the “Plan of Arrangement,” over 82% of votes cast were in favor. Prior to the meeting, the plan of arrangement was amended to broaden the range of the exchange ratio for Forbes Medi-Tech shares to a range of two to eight Forbes shares for each Newco share. The exchange ratio was adjusted in light of recent market prices, and to provide flexibility to the Board of Directors in an effort to help regain compliance with Nasdaq's minimum US$1 bid requirement. The actual exchange ratio will be announced as soon as it is set by the Board and will affect share, option and warrant holders equally.
"We appreciate the overwhelming support from shareholders," said Charles Butt, President and CEO of Forbes Medi-Tech. "We look forward to proceeding with our near-term objectives in merger and acquisition activity and strengthening the Company's financial position."
DOR BIOPHARMA INCORPORATED (OTCBB: DORB)
"Up 13.64% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/DORB.php
DOR BioPharma, Inc., a biopharmaceutical company, engages in the research and development of oral therapeutic products intended for areas of unmet medical needs and biodefense vaccines in the United States and internationally. It operates through two segments, BioTherapeutics and BioDefense. The BioTherapeutics segment develops orBec, an orally administered corticosteroid that exerts a potent and local anti-inflammatory effect in the mucosal tissue of the gastrointestinal tract; Oraprine, an oral suspension of azathioprine; and LPE and PLP systems for delivery of water-insoluble drugs. The BioDefense segment offers RiVax, ricin toxin vaccine, a heat stable toxin that is isolated and purified from the bean of the castor plant; and BT-VACC, the Botulinum toxin, a poisonous natural substance that causes acute, symmetric, and descending flaccid paralysis due to its action on peripheral cholinergic nerves. The company was founded in 1987 and is based in Ewing, New Jersey.
DORB News:
February 15 - DOR BioPharma Announces Named Patient Access Program for orBec(R) in South Korea in Collaboration With BL&H Co., Ltd.
DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced that it has entered into a Letter of Intent with BL&H Co., Ltd. (BL&H), a specialty pharmaceutical company based in Seoul, South Korea, pursuant to which BL&H will act as DOR's Sponsor with regard to the administration of a Named Patient Program (NPP) for orBec® to patients suffering from acute gastrointestinal Graft-versus-Host disease (GI GVHD) in South Korea.
The NPP is a compassionate use drug supply program administered by the Korea Orphan Drug Center (KODC) under which medical practitioners can legally supply investigational drugs to their patients who qualify. Under this program, investigational drugs can be administered through KODC to patients who are suffering from serious illnesses until the drug is approved by the Korea Food & Drug Administration. BL&H and DOR will share revenues generated by sales of orBec® through the NPP. DOR will manufacture and supply orBec® to BL&H, while BL&H will be responsible for all distribution costs in South Korea.
"We are very pleased to be working with DOR BioPharma on the NPP for orBec®," said Dong Chul Roh, President of BL&H. "There is a need for a new drug to treat acute GI GVHD as a result of allogeneic bone marrow/stem cell transplantation here in Korea. Given our focus on hospital-based products in hematology and oncology, we have been enthusiastically following the development of orBec® for quite some time. We are glad to be able to provide orBec®, the first directed therapy for patients suffering from GI GVHD, to Korean patients."
"This is another piece in our worldwide strategy of making orBec® available to patients who need it wherever possible," stated Christopher J. Schaber, PhD, President and CEO of DOR BioPharma. "We are happy to be working with BL&H to make orBec® available to GVHD patients through Korea's NPP program. BL&H has extensive expertise in the sales and marketing of several products in the hematology/oncology space and we look forward to a productive relationship with them. As we have stated before, we will continue to pursue similar types of programs in the United States, Europe and the rest of the world so that GI GVHD patients will have this important treatment option."
ABOUT BL&H COMPANY
BL&H is a privately owned pharmaceutical company based in South Korea. BL&H was established in 1999 with the aim of becoming a leader in the delivery of pharmaceuticals and services that fulfill unmet medical needs in the Korean market. BL&H specializes in hospital-based products in hematology, oncology, rheumatology and respiratory medicines. The management team has extensive experience in the pharmaceutical and healthcare sectors and in bringing specialty products to market.
CELL GENESYS INCORPORATED (NASD: CEGE)
"Up 12.69% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CEGE.php
Cell Genesys, Inc., a biotechnology company, engages in development and commercialization of biological therapies for cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company's clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. Its GVAX cancer Immunotherapies include Prostate Cancer, a phase 3 product for the treatment of prostate cancer; Pancreatic Cancer, a phase 2 product for pancreatic cancer; and Leukemia, a phase 2 product for the treatment of acute myelogenous leukemia and chronic myelogenous leukemia. The company's Oncolytic Virus Therapy includes CG0070, a phase 1 product for the treatment of recurrent bladder cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Amgen, Inc. The company was founded in 1988 and is headquartered in South San Francisco, California.
CEGE News:
February 15 - Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Cell Genesys, Inc. (NASD: CEGE) reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial in patients with metastatic, hormone refractory prostate cancer (HRPC). More than 400 patient-specific GVAX-induced antibody responses were identified in the sera of the treated patients by three different biochemical techniques confirming, as previously reported, that GVAX treatment results in a broad, multi-antigen immune response. An ongoing analysis of these GVAX-induced antibody responses has shown that at least two of the antibody responses are associated with patient survival, an association that is independent of the dose and number of treatments administered. These data will be presented today by Dr. Thomas Harding and colleagues from Cell Genesys at the American Society of Clinical Oncology's Genitourinary Cancer Symposium being held in San Francisco, California.
Cell Genesys has previously reported the results of two multicenter Phase 2 trials of GVAX immunotherapy for prostate cancer in metastatic HRPC. The second of these two trials enrolled 80 patients. The serum of 65 patients (the total number for whom adequate sera were available) were examined to determine each patient's immune response to two specific antigens, HLA-A24 and FLJ14668, following GVAX treatment. Thirty-four of 65 patients demonstrated an FLJ14668-specific antibody immune response. These 34 patients had a median survival of 43 months, compared to a median survival of 21 months achieved by the patients who did not generate anti-FLJ14668 antibodies (p=0.002). Twenty-two of these 65 patients received a dose of GVAX immunotherapy for prostate cancer comparable to that being evaluated in ongoing Phase 3 clinical trials. Of these 22 patients, 16 patients (73 percent) mounted an immune response to FLJ14668. These 16 patients achieved a median survival of 44.9 months. As previously reported, the median survival for all 22 patients in this treatment group was 35.0 months. Finally, of the 58 patients who were HLA-A24 genotype negative and therefore potentially able to mount anti-HLA-A24 specific antibody responses, 30 patients were found to be anti-HLA-A24 antibody positive. These 30 patients had a median survival of 43 months, compared to a median survival of 18 months in the patients who did not generate anti-HLA-A24 antibodies (p=0.05). Importantly, the apparent associations between the presence of these two specific antibody responses and survival were shown by multivariate analysis to be independent of both dose and duration of treatment.
"The findings being reported today indicate a potential association between two specific GVAX-induced antibody responses and patient survival, an association consistent with the proposed mechanism of action for this product. We look forward to expanding these findings in a prospective analysis of the sera of patients treated in our two randomized controlled Phase 3 trials," stated Peter K. Working, Ph.D., senior vice president of research and development at Cell Genesys. "Since GVAX immunotherapy for prostate cancer is a multi-antigen product that can induce a broad immune response, we believe we have a unique opportunity to identify the widest possible array of specific antibody responses that may be associated with clinical benefit."
Cell Genesys is currently evaluating GVAX immunotherapy for prostate cancer in two Phase 3 multicenter, randomized, controlled clinical trials. VITAL-1, which is fully enrolled with 626 patients, is designed to compare GVAX cancer immunotherapy to Taxotere® (docetaxel) chemotherapy plus prednisone in HRPC patients with metastatic disease who are asymptomatic with respect to cancer-related pain. The primary endpoint of the trial is an improvement in survival. An interim analysis of the trial was recently conducted by an independent data monitoring committee in the timeframe originally estimated and resulted in the recommendation to continue the trial. The company expects to have enough events to trigger the final analysis of VITAL-1 in the second half of 2009. VITAL-2, which the company expects to fully enroll with approximately 600 patients in the first half of 2009, is designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. The company expects to have enough events to trigger an interim analysis of VITAL-2 in the first half of 2009.
ABOUT GVAX CANCER IMMUNOTHERAPIES
GVAX cancer immunotherapies are non patient-specific investigational products comprised of whole tumor cells that have been modified to secrete GM- CSF (granulocyte-macrophagecolony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety. GVAX is administered via intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GVAX immunotherapy for prostate cancer in its bioreactor-based manufacturing plant in Hayward, California, a facility that is also capable of manufacturing the product for commercialization.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover’s Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated eight thousand dollars by a third party (Haynes Capital) for UOMO advertising and promotional services. OTCPicks.com has been compensated eight thousand dollars by a third party (StockPromoters.com) for RHGP advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
